Van Albert Hofmann tot 4-Pro-MET: geschiedenis van tryptamines

De geschiedenis van het tryptamineonderzoek begint met een fiets. Op 19 april 1943 fietste Albert Hofmann onder invloed van LSD — een ergoline, strikt genomen geen tryptamine, maar de vonk voor het psychedelisch onderzoek — door Basel. Wat volgde: 80 jaar onderzoek, verboden, renaissance en de ontwikkeling van substanties zoals 4-Pro-MET. Van Hofmanns laboratoria bij Sandoz tot de synthetische tryptaminen van de 21e eeuw.

Albert Hofmann synthesized LSD (lysergic acid diethylamide) at Sandoz Laboratories in Basel, Switzerland in 1938. Five years later came the accident that changed everything. On April 19, 1943 – now commemorated as "Bicycle Day" – Hofmann absorbed a small quantity through his skin and experienced altered perception during his ride home. LSD is a lysergamide, not a tryptamine. But Hofmann's discovery cracked open the door to systematic psychedelic research.

Tryptamines came next. In 1958, Hofmann synthesized psilocybin and psilocin from Psilocybe mexicana mushrooms. By 1960, he'd determined their chemical structures and developed synthetic production methods. These discoveries put 4-substituted tryptamines on the map alongside lysergamides and phenethylamines. And the research boom that followed was staggering: between 1950 and 1970, approximately 1,000 scientific papers were published on psychedelic tryptamines, and an estimated 40,000 patients received psilocybin or LSD in therapeutic settings.

Alexander 'Sasha' Shulgin (1925–2014) bracht Hofmanns werk naar een systematisch niveau. In zijn privélaboratorium in Californië synthetiseerde en testte hij honderden fenethylaminen en tryptaminen — waaronder 4-HO-MET, de actieve metaboliet van 4-Pro-MET.

TiHKAL (1997) documenteerde 55 tryptaminen met syntheseprotocollen en zelfexperimentdocumentatie. Over 4-HO-MET (vermelding #21) schreef Shulgin: 'Qualitatively a lot like psilocin. I started within the first half-hour, and at the max, I felt the same alteration of color and form' — dosis 10–20 mg, duur 4–6 uur.

Zijn aanpak was eenvoudig en briljant: één variabele wijzigen (bv. de N-substitutie), de rest constant houden, het effect documenteren. Dit legde de grondslag voor modern structuur-activiteitsrelatie-onderzoek (SAR) bij tryptaminen. 4-Pro-MET staat in deze traditie: het varieert de ester op positie 4 (propionyloxy in plaats van acetyloxy) bij hetzelfde N-methyl-N-ethylpatroon.

The modern psychedelic renaissance began in 2006 when Roland Griffiths' team at Johns Hopkins published their landmark psilocybin study – demonstrating its ability to occasion mystical-type experiences with lasting positive effects. Clinical trials followed fast: by 2026, over 15 Phase II/III trials are active or completed for psilocybin alone, targeting treatment-resistant depression, PTSD, alcohol use disorder, and end-of-life anxiety.

The research chemical market expanded in parallel. 4-HO-MET appeared as a designer substance around 2008, 4-AcO-MET and 4-AcO-DMT gained popularity through the mid-2010s, and 4-Pro-MET emerged in August/September 2025 as the latest iteration of the 4-substituted tryptamine prodrug strategy. Each compound applies Shulgin's foundational chemistry to generate legal variants with predictable pharmacological profiles.